MOUNTAIN SIDE, NJ - (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced that Proteonomix's application to list on the bulletin board has been approved and the Company's shares are now available for trading on the OTC Bulletin Board with the symbol: "PROT," effective immediately. Proteonomix common stock was previously quoted on the Pink Sheets.
Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, "We are delighted that the long process to list our shares on the bulletin board has been accomplished. This is another critical move leading to a listing on a major exchange such as NASDAQ and is indicative of the progress that Proteonomix has made in recent months. We would particularly like to thank our understanding and loyal shareholders. We hope that the move to the bulletin board will increase Proteonomix's exposure to investors and improve liquidity in the trading of its shares, leading, we believe, to increased shareholder value."
For further information about the Company visit our web site: www.proteonomix.com or contact Wolfe Axelrod Weinberger Associates at: 212-370-4500.
About Proteonomix, Inc. and subsidiaries:
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. a wholly owned subsidiary of Proteonomix has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix' operating subsidiary. The Sperm Bank of New York, Inc., engaged in reproductive tissue banking, including sperm, ova, ovarian tissue and testicular tissue, is a subsidiary of National Stem Cell, Inc. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit www.proteonomix.com, www.proteoderm.com, www.otcqb.com and www.sec.gov.
Forward-looking statments:
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made. |
